ENHERTU, an approved antibody-drug conjugate, is specifically crafted for HER2-targeted therapy in breast and gastric cancers that express HER2. The widespread presence of HER2 expression extends to diverse solid tumors beyond breast and gastric cancers. Existing treatments, even those aimed at HER2, demonstrate restricted efficacy in these patient groups, highlighting a significant gap in medical care. As of the data cutoff on June 8, 2023, 267 patients diagnosed with various cancers, including biliary tract, bladder, cervical, endometrial, ovarian, pancreatic, or other tumors, had undergone systemic treatment. With a median follow-up of 12.75 months, 40.8% of these patients had experienced ≥3 lines of therapy. Across the entire patient cohort, the investigator-assessed objective response rate (ORR) stood at 37.1%, with a median duration of response (mDOR) lasting 11.3 months. Apart from that, the median progression-free survival (mPFS) was 6.9 months, and the median overall survival (mOS) reached 13.4 months. In the safety evaluation, treatment-emergent adverse events (TEAEs) related to the drug were most frequently observed in more than 10% of patients. Additionally, Grade ≥3 TEAEs attributable to the drug were experienced by 40.8% of patients. Overall, the safety profile of T-DXd remained in line with the established expectations.

Conclusion

T-DXd highlights substantial and clinically relevant efficacy in various HER2-expressing solid tumors, with enduring responses translating into significant progression-free and overall survival benefits. The findings from DESTINY-PanTumor02 underscore the potential of T-DXd as a promising, tumor-agnostic therapy for individuals with HER2-expressing solid tumors.

Reference reports by DelveInsight for more in-depth analysis and key coverage - 

• Non-Muscle Invasive Bladder Cancer Market Insight, Epidemiology, and Market Forecast
• Bladder Cancer Market Insight, Epidemiology, and Market Forecast